EMA Panel Recommends EU Approval of Revolution Medicines’ Pancreatic Cancer Drug
The European Medicines Agency committee recommended approval of Rasonque for adults with pancreatic cancer that has spread and worsened after at least one prior treatment.
On Thursday, a European Medicines Agency committee recommended EU approval of Revolution Medicines' Rasonque (NASDAQ: RVMD) for adults with pancreatic cancer that has spread and progressed after at least one previous treatment. Rasonque received accelerated approval in the US in August.